Biblio
] , “Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD).”, J Alzheimers Dis, vol. 101, no. 1, pp. 353-367, 2024.
, “Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD).”, J Alzheimers Dis, vol. 58, no. 4, pp. 1217-1228, 2017.
